Psilocybin is under clinical development by Tryptamine Therapeutics and currently in Phase II for Irritable Bowel Syndrome. According to GlobalData, Phase II drugs for Irritable Bowel Syndrome have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Psilocybin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Psilocybin overview
Psilocybin (TRP-8802) is under development for the treatment of fibromyalgia, binge eating disorder and irritable bowel syndrome (IBS). It is administered orally as a capsule and also administered intravenously. It is a psychedelic drug.
It was under development for the treatment of hypothalamic obesity and chronic pain conditions.
Tryptamine Therapeutics overview
Tryptamine Therapeutics is a clinical-stage biotechnology company that develops transformative medicine for diseases lacking effective first-line treatments. The company’s pipeline products include TRP-8803 a proprietary formulation of IV-infused psilocin and TRP-8802 treats binge eating disorder, fibromyalgia and irritable bowel syndrome. Its synthetic psilocybin and IV-infused psilocin, are used in conjunction with psychotherapy to address neuropsychiatric disorders. Tryptamine Therapeutics products are used in the healthcare industry, specifically for the treatment of conditions such as chronic pain, and certain types of depression, pain and obsessive-compulsive disorders. Tryptamine Therapeutics is headquartered in Camberwell, Victoria, Australia.
For a complete picture of Psilocybin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
